BriaCell Therapeutics Corp.
BCTX
$2.02
-$0.05-2.42%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.92% | -4.82% | -7.64% | -47.75% | -9.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.43% | -27.06% | -39.40% | -25.15% | 62.58% |
| Operating Income | 31.43% | 27.06% | 39.40% | 25.15% | -62.58% |
| Income Before Tax | -467.86% | 44.08% | -197.83% | 48.37% | 134.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -467.86% | 44.08% | -197.83% | 48.37% | 134.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 317.02% | 18.07% | -36.53% | -- | -- |
| Net Income | -457.09% | 44.30% | -196.68% | 49.80% | 135.05% |
| EBIT | 31.43% | 27.06% | 39.40% | 25.15% | -62.58% |
| EBITDA | 31.70% | 27.30% | 39.69% | 26.05% | -62.62% |
| EPS Basic | -201.85% | 78.02% | -158.00% | 55.28% | 134.03% |
| Normalized Basic EPS | -200.05% | 78.07% | -157.59% | 56.04% | 134.31% |
| EPS Diluted | -201.88% | 78.02% | 55.70% | 53.74% | 133.54% |
| Normalized Diluted EPS | -200.05% | 78.07% | -160.09% | 56.04% | 134.31% |
| Average Basic Shares Outstanding | 250.62% | 153.39% | 66.71% | 12.25% | 2.99% |
| Average Diluted Shares Outstanding | 250.62% | 153.39% | 59.76% | 12.25% | 2.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |